Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with systemic sclerosis (scleroderma) based on standard medical criteria
- Your scleroderma symptoms (other than Raynaud's phenomenon) started less than 84 months (7 years) before the start of the study
- A chest scan (HRCT) shows that scleroderma has affected your lungs, with more than 10% of your lungs involved, confirmed by an independent reviewer
- You have either the limited or diffuse form of scleroderma (up to 40% of participants may have the limited form)
- You have been taking a medication called mycophenolate (MMF) at a dose of at least 2g per day for at least 3 months before the study starts, OR you are on the highest dose you can tolerate if you have had side effects from it, OR you are taking a different approved immune-suppressing medication at a stable dose for at least 4 weeks before the study starts
Who may not be able to join:
- Your lung function test results show severely reduced lung capacity (confirm with trial site for exact values)
- You have high blood pressure in the arteries of your lungs requiring intravenous treatment, or you show signs of right-sided heart failure
- Your recent chest scan shows another lung condition that could interfere with the study results
- You have taken steroid medications (such as prednisone) at doses higher than 10mg per day within the 2 weeks before the study starts
- You are currently taking more than one immune-suppressing medication at the same time
- You have received certain specific medications — including rituximab, tocilizumab, cyclophosphamide, or certain others — within the past 12 months before the study starts
- You have another rheumatic autoimmune disease in addition to scleroderma, or you are a heavy smoker of tobacco or nicotine-containing products
- You have a history of, or have tested positive for, a condition called anti-synthetase syndrome (Jo-1 positive)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lisa Carey, aTyr Pharma, Inc.
Phone: 877-215-5731
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Absolute change from baseline in forced vital capacity (FVC) in mL; Annual rate of decline in FVC in mL; Annual rate of decline in FVC in percent predicted; Change in HRCT fibrosis score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.